S-8: Securities offered to employees pursuant to employee benefit plans Post author:andrewkaretas Post published:March 13, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingS-8: Securities offered to employees pursuant to employee benefit plans
10-K: Annual report which provides a comprehensive overview of the company for the past year Post author:andrewkaretas Post published:March 13, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading10-K: Annual report which provides a comprehensive overview of the company for the past year
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:March 13, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
SCHEDULE 13G/A – Description Post author:andrewkaretas Post published:March 7, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSCHEDULE 13G/A – Description
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:March 5, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
3: Initial filing by director officer or owner of more than ten percent Post author:andrewkaretas Post published:March 4, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading3: Initial filing by director officer or owner of more than ten percent
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:February 25, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:February 20, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing Post author:andrewkaretas Post published:February 18, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
SCHEDULE 13G – Description Post author:andrewkaretas Post published:February 14, 2025 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSCHEDULE 13G – Description
